問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
Division of Others
下載
2020-01-01 - 2026-12-31
Condition/Disease
Advanced or metastatic malignancies
Test Drug
Repotrectinib
Participate Sites2Sites
Recruiting2Sites
2021-09-01 - 2025-08-31
Participate Sites5Sites
Recruiting5Sites
2021-01-01 - 2023-12-31
Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations
LY3410738
Recruiting1Sites
Terminated1Sites
2018-05-31 - 2027-12-31
Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
Pembrolizumab (MK-3475)/KEYTRUDA
Participate Sites4Sites
Recruiting4Sites
2020-08-31 - 2026-03-31
Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Oregovomab
Participate Sites6Sites
Recruiting6Sites
2020-08-01 - 2023-11-23
Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
ENTRECTINIB (RXDX-101)
2021-03-17 - 2025-06-15
Participate Sites8Sites
Recruiting8Sites
2021-05-10 - 2022-09-26
Relapsed/Refractory Multiple Myeloma
AMG701
Participate Sites3Sites
Terminated3Sites
2021-08-02 - 2026-09-18
2022-01-01 - 2025-08-18
Division of Infectious Disease
全部
